ScienceUnited States1 sourcesNeutral

Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC

1 April 2026 - Chinese biopharmaceutical company Abbisko Therapeutics Co Ltd (HKEX:02256) announced on Tuesday that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor i...

M2 Pharma

via M2 Pharma

April 1, 2026 | 12:00 AM UTCUpdated 1d ago

Share Read original

Read the full article at M2 Pharma →

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

M2 Pharma

NewsDataUS

Comments

0 comments

Be respectful and constructive.

Loading comments...

Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC

Source Verification

Comments

Gyokeres to the rescue as Sweden beat Poland in thriller to reach World Cup

ORNL to Feature Transformative Tech at ARPA-E Summit

Related Articles

Permanent Change to Alaska Sparks Alarm

Thursday Essay: What in the Actual Hell Is Going on in China?

Eddy Moratin, Lift Orlando, elevate neighbors through ‘redemptive work'